Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for curing branchial asthma

A technology for bronchial asthma and a composition is applied in the field of the composition of salmeterol and budesonide, which can solve the problems of inconvenient use, single curative effect, large dosage and the like, and achieves long curative effect duration, good comprehensive effect, Wide range of effects to choose from

Inactive Publication Date: 2003-06-25
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The above-mentioned two kinds of medicines are used to treat patients with respiratory system such as bronchial asthma and have good curative effect, but generally the dosage is relatively large, the curative effect is single, and it is inconvenient to use separately

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for curing branchial asthma
  • Composition for curing branchial asthma
  • Composition for curing branchial asthma

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0029] Salmeterol 2.5g

[0030] Budesonide 8.0g

[0031] Ethanol 750g

[0032] Propylene glycol 150g

[0033] Dichlorodifluoromethane 1500g

[0034] Vitamin C 7.5g

[0035]Preparation process: add the prescribed amount of salmeterol and budesonide into the well-stirred vitamin C, ethanol and propylene glycol, stir, heat in a warm water bath to dissolve the raw materials, filter with a sand core funnel, fill in divided doses, and seal Dosage valve system, respectively pressurize and inject dichlorodifluoromethane to obtain, theoretically fill 1000 bottles, and the filling yield is above 85%. After 30 minutes of leak detection in a water bath at 45-50°C, there is no leakage. Each bottle is 50 presses, and each press contains 50 μg of salmeterol and 160 μg of budesonide. Example 2

example 2

[0036] Salmeterol 2.5g

[0037] Budesonide 10.0g

[0038] Ethanol 750g

[0039] Propylene glycol 150g

[0040] Dichlorodifluoromethane 1500g

[0041] Vitamin C 7.5g

[0042] Preparation process: add the prescribed amount of salmeterol and budesonide into the well-stirred vitamin C, ethanol and propylene glycol, stir, heat in a warm water bath to dissolve the raw materials, filter with a sand core funnel, fill in divided doses, and seal Dosage valve system, respectively pressurize and inject dichlorodifluoromethane to obtain, theoretically fill 1000 bottles, and the filling yield is above 85%. After 30 minutes of leak detection in a water bath at 45-50°C, there is no leakage. Each bottle is 50 presses, and each press contains 50 μg of salmeterol and 200 μg of budesonide. Example 3

example 3

[0043] Salmeterol Xinafoate 5.09g

[0044] Budesonide 10.0g

[0045] Ethanol 750g

[0046] Glycerin 150g

[0047] Trichlorofluoromethane 1500g

[0048] Sodium metabisulfite 7.5g

[0049] Preparation process: add the prescribed amount of salmeterol xinafoate and budesonide into the well-stirred sodium metabisulfite, ethanol and glycerin, stir, heat in a warm water bath to dissolve the raw materials, filter with a sand core funnel, and fill in divided doses , sealing the dose valve system, and injecting trichlorofluoromethane under pressure respectively to obtain the product. Theoretical filling is 1000 bottles, and the filling yield is above 85%. After 30 minutes of leak detection in a water bath at 45-50°C, there is no leakage. Each bottle is 50 presses, and each press contains 70 μg of salmeterol and 200 μg of budesonide. Example 4

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a kind of medicine composite for treating branchial asthma. The medicine composite consists of active component including salmeterol or its medicinal salt and budesonide in the molar ratio of 1 to 0.38-20, as well as non-active components including solvent, cosolvent, propellant, antioxidant, dilutent and lubricant. The present invention has large range of medicine dosage, long lasting period and high comprehensive effect, and may be prepared into various preparation forms.

Description

technical field [0001] The invention relates to the treatment of bronchial asthma, in particular provides a composition of salmeterol and budesonide for treating bronchial asthma. The new composition of salmeterol and budesonide with pharmaceutically active substances can be made into compound inhalation aerosol and powder, non-inhalation aerosol and powder and compound spray to effectively treat bronchial asthma sick. Background technique [0002] Bronchial asthma is a chronic airway inflammation characterized by reversible airway obstruction and increased airway reactivity. Airway obstruction is caused by two factors: increased secretions caused by bronchial mucosal inflammation, mucosal edema, and smooth muscle spasm stimulated by inflammation; and Increased airway reactivity is also the result of damage to the bronchial epithelium due to airway inflammation. It is recognized that only by controlling the inflammation of the airway mucosa can the ultimate goal of reducin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/58A61P11/06
Inventor 孙勇
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com